Do Sandoz’ Q2 Results Indicate US Bottom Is In Sight?
Novartis Unit Raises Annual Guidance As Q2 ‘Outweighs Expectations’
Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.
